CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications.
Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法已被公认为治疗血液系统恶性肿瘤患者最先进、最有效的策略之一。然而,在实体瘤治疗中尚未观察到类似的结果。原因之一是肿瘤具有对T细胞浸润和效应活性极为不利的微环境,这主要是由于存在高度抑制性的细胞因子、缺氧和活性氧。利用细胞因子的功能,新的第四代CAR构建体已被开发出来,既能靶向肿瘤细胞,又能额外释放有助于T细胞细胞毒性的细胞因子。本文还讨论了制造工艺,包括在T细胞扩增和分化中使用细胞因子。最后,探讨了临床方面以及细胞因子对接受CAR-T 细胞治疗患者临床状况的影响,如细胞因子释放综合征。因此,本综述旨在强调细胞因子作为细胞疗法主要参与者之一的重要性。
CAR-T cell therapies have been recognized as one of the most advanced and efficient strategies to treat patients with hematologic malignancies.
However, similar results have not been observed for the treatment of solid tumors. One of the explanations is the fact that tumors have extremely hostile microenvironments for the infiltration and effector activity of T-cells, mainly due to the presence of highly suppressive cytokines, hypoxia, and reactive oxygen species.
Taking advantage of cytokines functionally, new fourth-generation CAR constructs have been developed to target tumor cells and additionally release cytokines that can contribute to the cytotoxicity of T-cells. The manufacturing process, including the use of cytokines in the expansion and differentiation of T cells, is also discussed.
Finally, the clinical aspects and the influence of cytokines on the clinical condition of patients, such as cytokine release syndrome, who receive treatment with CAR-T cells are addressed.
Therefore, this review aims to highlight how important cytokines are as one of the major players of cell therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。